CO2023001681A2 - Bancos de células t específicas para antígeno universal y métodos para producir y usar los mismos terapéuticamente - Google Patents
Bancos de células t específicas para antígeno universal y métodos para producir y usar los mismos terapéuticamenteInfo
- Publication number
- CO2023001681A2 CO2023001681A2 CONC2023/0001681A CO2023001681A CO2023001681A2 CO 2023001681 A2 CO2023001681 A2 CO 2023001681A2 CO 2023001681 A CO2023001681 A CO 2023001681A CO 2023001681 A2 CO2023001681 A2 CO 2023001681A2
- Authority
- CO
- Colombia
- Prior art keywords
- specific
- antigen
- methods
- producing
- minibanks
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 7
- 102000036639 antigens Human genes 0.000 title abstract 7
- 108091007433 antigens Proteins 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 3
- 238000010276 construction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Las modalidades de la divulgación incluyen composiciones de células T específicas para antígeno universal, y métodos para producir y usar las mismas. Las modalidades de la divulgación también incluyen métodos para identificar y seleccionar donadores adecuados para usarse en la construcción de minibancos de donadores de líneas de células T específicas para antígeno; minibancos de donadores de líneas de células T específicas para antígeno; composiciones de células T específicas para antígeno universal que comprenden una pluralidad de las líneas de células T específicas para antígeno de estos minibancos de donadores, y bancos de donadores compuestos de una pluralidad de estos minibancos. La presente divulgación incluye métodos para tratar una enfermedad o condición que comprende administrar a un paciente al menos una composición de células T específicas para antígeno universal divulgada en la presente.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880006P | 2019-07-29 | 2019-07-29 | |
| US201962887802P | 2019-08-16 | 2019-08-16 | |
| US202063054161P | 2020-07-20 | 2020-07-20 | |
| PCT/US2020/044080 WO2021021937A1 (en) | 2019-07-29 | 2020-07-29 | Antigen-specific t cell banks and methods of making and using the same therapeutically |
| PCT/US2021/016266 WO2022025984A1 (en) | 2019-07-29 | 2021-02-02 | Universal antigen-specific t cell banks and methods of making and using the same therapeutically |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023001681A2 true CO2023001681A2 (es) | 2023-05-08 |
Family
ID=74230834
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0001972A CO2022001972A2 (es) | 2019-07-29 | 2022-02-23 | Bancos de células t específicas de antígeno y métodos para elaborar y usar los mismos terapéuticamente |
| CONC2023/0001681A CO2023001681A2 (es) | 2019-07-29 | 2023-02-15 | Bancos de células t específicas para antígeno universal y métodos para producir y usar los mismos terapéuticamente |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0001972A CO2022001972A2 (es) | 2019-07-29 | 2022-02-23 | Bancos de células t específicas de antígeno y métodos para elaborar y usar los mismos terapéuticamente |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230295565A1 (es) |
| EP (2) | EP4003378A4 (es) |
| JP (2) | JP2022542968A (es) |
| KR (2) | KR20220051348A (es) |
| CN (2) | CN114502180A (es) |
| AU (2) | AU2020322790A1 (es) |
| BR (2) | BR112022001596A2 (es) |
| CA (2) | CA3149145A1 (es) |
| CO (2) | CO2022001972A2 (es) |
| IL (2) | IL300179A (es) |
| MX (2) | MX2022001322A (es) |
| WO (2) | WO2021021937A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| WO2013119947A1 (en) | 2012-02-09 | 2013-08-15 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
| IL302514A (en) * | 2012-06-11 | 2023-07-01 | Wilson Wolf Mfg Corporation | Improved cell culture methods for stress cell therapy |
| JP6999941B2 (ja) | 2015-09-18 | 2022-02-10 | ベイラー カレッジ オブ メディスン | 病原体からの免疫原性抗原同定および臨床的有効性との相関 |
| CN114452388A (zh) * | 2022-03-07 | 2022-05-10 | 北京大学第一医院 | 一种降低血循环系统中eb病毒拷贝数的方法和系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0107628D0 (en) * | 2001-03-27 | 2001-05-16 | Avidex Ltd | Substances |
| CA2930784C (en) * | 2013-11-22 | 2023-01-31 | Cellectis | Method for generating batches of allogeneic t cells with averaged potency |
| ES2846747T3 (es) * | 2014-11-05 | 2021-07-29 | Memorial Sloan Kettering Cancer Center | Procedimientos para seleccionar la línea de células T y su donante para terapia celular adoptiva |
| EP3756676B1 (en) * | 2015-06-26 | 2023-01-11 | Memorial Sloan Kettering Cancer Center | Methods of treating cmv retinitis by t cell therapy |
| EP3463399A4 (en) * | 2016-05-25 | 2020-03-18 | The Council of the Queensland Institute of Medical Research | METHODS OF TREATING AUTOIMMUNE DISEASE USING ALLOGENIC T CELLS |
| TW201814042A (zh) * | 2016-09-26 | 2018-04-16 | 新加坡商泰莎治療私人有限公司 | T細胞擴展方法 |
| EP3641807A4 (en) * | 2017-06-22 | 2021-04-21 | The Westmead Institute For Medical Research | ADOPTIVE T-CELL THERAPY 2 |
| KR20200051714A (ko) * | 2017-09-06 | 2020-05-13 | 난트 홀딩스 아이피, 엘엘씨 | Hla 조직 매칭 및 그에 관한 방법(hla tissue matching and methods therefor) |
-
2020
- 2020-07-29 WO PCT/US2020/044080 patent/WO2021021937A1/en active Application Filing
- 2020-07-29 CA CA3149145A patent/CA3149145A1/en active Pending
- 2020-07-29 AU AU2020322790A patent/AU2020322790A1/en active Pending
- 2020-07-29 BR BR112022001596A patent/BR112022001596A2/pt unknown
- 2020-07-29 JP JP2022506160A patent/JP2022542968A/ja active Pending
- 2020-07-29 MX MX2022001322A patent/MX2022001322A/es unknown
- 2020-07-29 CN CN202080067987.2A patent/CN114502180A/zh active Pending
- 2020-07-29 EP EP20847823.0A patent/EP4003378A4/en active Pending
- 2020-07-29 KR KR1020227006698A patent/KR20220051348A/ko unknown
-
2021
- 2021-02-02 IL IL300179A patent/IL300179A/en unknown
- 2021-02-02 JP JP2023505972A patent/JP2023536840A/ja active Pending
- 2021-02-02 AU AU2021318102A patent/AU2021318102A1/en active Pending
- 2021-02-02 WO PCT/US2021/016266 patent/WO2022025984A1/en active Application Filing
- 2021-02-02 EP EP21848816.1A patent/EP4188397A1/en active Pending
- 2021-02-02 CA CA3177064A patent/CA3177064A1/en active Pending
- 2021-02-02 CN CN202180066389.8A patent/CN116261466A/zh active Pending
- 2021-02-02 US US18/018,552 patent/US20230295565A1/en active Pending
- 2021-02-02 BR BR112023001642A patent/BR112023001642A2/pt not_active Application Discontinuation
- 2021-02-02 MX MX2023001287A patent/MX2023001287A/es unknown
- 2021-02-02 KR KR1020237006817A patent/KR20230058398A/ko unknown
-
2022
- 2022-01-27 IL IL290163A patent/IL290163A/en unknown
- 2022-02-23 CO CONC2022/0001972A patent/CO2022001972A2/es unknown
-
2023
- 2023-02-15 CO CONC2023/0001681A patent/CO2023001681A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023001287A (es) | 2023-03-22 |
| CA3149145A1 (en) | 2021-02-04 |
| WO2021021937A1 (en) | 2021-02-04 |
| CN116261466A (zh) | 2023-06-13 |
| JP2023536840A (ja) | 2023-08-30 |
| US20230295565A1 (en) | 2023-09-21 |
| EP4003378A4 (en) | 2023-08-23 |
| AU2020322790A1 (en) | 2022-03-03 |
| BR112023001642A2 (pt) | 2023-10-03 |
| BR112022001596A2 (pt) | 2022-06-07 |
| MX2022001322A (es) | 2022-05-24 |
| WO2022025984A1 (en) | 2022-02-03 |
| EP4188397A1 (en) | 2023-06-07 |
| IL290163A (en) | 2022-03-01 |
| AU2021318102A1 (en) | 2023-03-16 |
| JP2022542968A (ja) | 2022-10-07 |
| KR20220051348A (ko) | 2022-04-26 |
| CO2022001972A2 (es) | 2022-04-08 |
| KR20230058398A (ko) | 2023-05-03 |
| CN114502180A (zh) | 2022-05-13 |
| IL300179A (en) | 2023-03-01 |
| EP4003378A1 (en) | 2022-06-01 |
| CA3177064A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023001681A2 (es) | Bancos de células t específicas para antígeno universal y métodos para producir y usar los mismos terapéuticamente | |
| CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| CO2020015153A2 (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| AR100225A2 (es) | Anticuerpos anti-factor d humanizados y usos de los mismos | |
| BR112019001923A2 (pt) | moduladores de nmda de espiro-lactama e métodos de sua utilização | |
| CL2019002671A1 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1. | |
| AR078346A1 (es) | Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano | |
| AR071510A1 (es) | Anticuerpos anti- factor d humanizados y sus usos | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| DOP2020000160A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
| CO2022000402A2 (es) | Uso de linfocitos t con receptor de antígeno quimérico e inhibidores de linfocitos citolíticos naturales para el tratamiento del cáncer | |
| CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
| CL2020003008A1 (es) | Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas | |
| ECSP19066134A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| ECSP23076906A (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
| CL2022000790A1 (es) | Método para tratar vih con cabotegravir y rilpivirina | |
| ECSP22004680A (es) | Anticuerpos anti-angpt2 | |
| CL2022001476A1 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
| AR120038A1 (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares | |
| CO2022003324A2 (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares | |
| PE20230181A1 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso |